Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964503 | 1.00 | LMNA (0.33) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4963313 | 0.90 | PKM (0.34) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4962824 | 0.86 | PKM (0.33) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4962397 | 0.86 | PKM (0.35) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4965989 | 0.86 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4963385 | 0.85 | MEN1 (0.36) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL5420984 | 0.85 | SMN1; SMN2 (0.35) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4966779 | 0.85 | PKM (0.37) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4962798 | 0.85 | PKM (0.34) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL4966404 | 0.85 | PKM (0.33) | LMNASMN1; SMN2L3MBTL1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934220-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007042883-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | LMNA 3259/4885SMN1; SMN2 4080/4885L3MBTL1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.